Core Viewpoint - Verastem Oncology has decided to discontinue the RAMP 203 clinical trial for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) to reallocate resources towards the clinical development of VS-7375, an oral KRAS G12D inhibitor, targeting advanced NSCLC and other solid tumors [1]. Group 1 - Verastem Oncology is a biopharmaceutical company focused on developing new medicines for patients with RAS/MAPK pathway-driven cancers [1]. - The decision to discontinue the RAMP 203 trial was based on the evaluation of interim data [1]. - The company aims to concentrate its efforts on the development of VS-7375, which is positioned as a promising treatment option for advanced NSCLC and other solid tumors [1].